title: Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine.
abstract: Seventy-four patients with one to eight proven intraaxial brain metastases received a total cumulative dose of 0.2 mmol/kg bodyweight gadobenate dimeglumine, administered as sequential injections of 0.05, 0.05 and 0.1 m mol/kg over a 20-min period. MR imaging was performed before the first administration (T2- and T1-weighted sequences) and after each injection of contrast agent (T1-weighted sequences only). Quantitative assessment of images revealed significant (P <0.01) dose-related increases in lesion-to-brain (L/B) ratio and percent enhancement of lesion signal intensity. Qualitative assessment by two independent, blinded assessors revealed additional lesions in 22%, 25% and 38% (assessor 1) and 29%, 32% and 34% (assessor 2) of patients after each cumulative dose when compared with combined T1- and T2-weighted pre-contrast images. Significantly more lesions (P < 0.01) were noted by both assessors after the first injection and by one assessor after each subsequent injection. For patients with just one lesion observed on unenhanced T1- and T2-weighted images, additional lesions were noted in 12%, 16% and 28% of patients by assessor 1 following each dose and in 24%, 27% and 30% of patients by assessor 2. Contemporaneously, diagnostic confidence was increased and lesion conspicuity improved over unenhanced MRI. For patients with one lesion observed after an initial dose of 0.05 mmol/kg, additional lesions were noted by assessors 1 and 2 in 9.1% and 11.8% of patients, respectively, after a cumulative dose of 0.1 mmol/kg and in a further 9.1% and 5.9% of patients, respectively, after a cumulative dose of 0.2 mmol/kg. No safety concerns were apparent.
authors.affiliation: Clinique de Neuroradiologie, Hôpital Erasme, Brussels, Belgium. dbaleri@ulb.ac.be
authors.forename: D
authors.initials: D
authors.lastname: Balériaux
authors.forename: C
authors.initials: C
authors.lastname: Colosimo
authors.forename: J
authors.initials: J
authors.lastname: Ruscalleda
authors.forename: M
authors.initials: M
authors.lastname: Korves
authors.forename: G
authors.initials: G
authors.lastname: Schneider
authors.forename: K
authors.initials: K
authors.lastname: Bohndorf
authors.forename: G
authors.initials: G
authors.lastname: Bongartz
authors.forename: M A
authors.initials: MA
authors.lastname: van Buchem
authors.forename: M
authors.initials: M
authors.lastname: Reiser
authors.forename: K
authors.initials: K
authors.lastname: Sartor
authors.forename: M W
authors.initials: MW
authors.lastname: Bourne
authors.forename: P M
authors.initials: PM
authors.lastname: Parizel
authors.forename: G R
authors.initials: GR
authors.lastname: Cherryman
authors.forename: I
authors.initials: I
authors.lastname: Salerio
authors.forename: A
authors.initials: A
authors.lastname: La Noce
authors.forename: G
authors.initials: G
authors.lastname: Pirovano
authors.forename: M A
authors.initials: MA
authors.lastname: Kirchin
authors.forename: A
authors.initials: A
authors.lastname: Spinazzi
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D003287:Contrast Media; D005260:Female; D005682:Gadolinium; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives*; D008875:Middle Aged; D009942:Organometallic Compounds; D011446:Prospective Studies; D012449:Safety
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium